In Vitro Susceptibility Pattern of Tigecycline against MRSA, ESBL Producing Escherichia coli, Klebsiella Species and Acinetobacter Isolates in a Rural Tertiary Care Hospital


  • Burdwan Medical College, Department of Microbiology, Bardhaman, India
  • Chittaranjan National Cancer Institute, Department of Oncosurgery, Kolkata, India


Background: Tigecycline is the first commercially available glycycline, derivatives of the tetracycline antibiotics, having enhanced activity against various pathogens. In vitro activity has been demonstrated against multi drug resistant Gram positive and Gram negative pathogens like MRSA, ESBL producing Esch.coli and Klebsiella spp. and Acinetobacter.

Objective: To determine Tigecycline in vitro susceptibility pattern in MRSA, ESBL producing Esch.coli and Klebsiella spp. and Acinetobacter spp.

Material and Methods: Investigations were carried out from August 2012-January 2014 to detect MRSA,ESBL producing Escherichia coli and Klebsiella spp. as well as Acinetobacter spp. by using a standard protocols and Tigecycline in-vitro susceptibility testing was done by Kirby Bauer Disc diffusion method and it's MIC value against resistant isolates was evaluated.Statistical analysis was done by Fishers extract method.

Result: Out of 107 Staphylococcus aureus isolates 52(48.59%) were MRSA, none of them showed resistance to Tigecycline. Out of 82 Esch.coli isolates 14 (i.e 17.07%) were ESBL producers, none of them showed resistance to Tigecycline.Out of 67 Klebsiella isolates 21 (i.e 31.34%) were ESBL producers out of which only 1 (i.e 4.76%) was resistant to Tigecycline.Out of 19 Acinetobacter spp.isolated 3 (i.e 15.78%) were resistant to Tigecycline. The MIC range for ESBL producing Eschcoli, Klebsiella spp., MRSA and acinetobacter spp were 0.14-0.45 μg/ml,0.25-2.4 μg/ml,0.12-0.26 μg/ml, 1-3.2 μg/ml respectively.

Conclusion: The results of the study confirm the excellent in vitro activity of Tigecycline against Gram positive and Gram negative multidrug resistant pathogens.


Tigecycline, Susceptibility, MRSA, ESBL Producing Klebsiella Spp, Acinetobacter.

Subject Discipline


Full Text:


Nordmann, PG Cuzon, T Naas. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis 2009;9(4):228-36.

Lee SY, Kuti JL, Nicolau DP. Polymyxins: older antibiotics for a new threat. Conn Med 2006;70(1):25-8.

Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;


Zinner Stephen H. Overview of antibiotic use and resistance: Setting the stage for Tigecycline. Clin Infect Dis 2005;41(5):289-92.

Rossi F, Andreazzi D. Overview of tigecycline and its role in the era of antibiotic resistance. Braz J Infect Dis 2006;10(3):203-16.

Wyeth Pharmaceuticals. Tygacil (tigecycline) for injection [Package insert]. 2005. Wyeth Pharmaceuticals Inc., Philadelphia, PA

Garrison MW, Nuemiller JJ. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Int J Antimicrob Agents 2007;29(2):191-6.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse E J. The pharmacokinetic/ pharmacodynamic proile of tigecycline - new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52(3):165-71.

J Gerald Collee, Barrie P Marmion, Andrew G Fraser, Anthony Simmons editors. Mackey & McCartney Practical Medical Microbiology 14th ed. India: Churchill Livingstone; 1999.p.131-150.

Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, et al. editors. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. 16th ed. Philadelphia: Lippincott Williams and Wilkins;2006.p.353-355

Performance Standards for Antimicrobial Susceptibility Testing; Twenty Second Informational Supplement M100-S22;32No.3;CLSI 2012.

Bijayini Behera, Anupam Das, Purva Mathur, Arti Kapil, Ravisekhar Gadepalli, Benu Dhawan. Tigecycline susceptibility report from an Indian tertiary care hospital. Indian J Med Res 2009;129(4):446-450.

Rossi F, García P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobial resistance in Latin America (20042007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect

Dis 2008;12(5):405-15.

Fernandez Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C. Argentinean Tigecycline Surveillance Group. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina Chemotherapy 2009;55(1):20-7.

Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009;34(2):121-30.

Anand Manoharan, Saradiya Chatterjee, S Madhan, Dilip Mathai. Evaluation of Tigecycline activity an clinical isolates among indian medical centers. Indian journal of Pathology and Microbiology2010:53(4):734-737.

Araj GF, Ibrahim GY. Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country. Diagn Microbiol Infect Dis 2008;62(4):411-5.

Jamal WY, Al Hashem G, Khodakhast F, Rotimi VO. Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBLproducing strains. J Chemother 2009; 21(3):261-6.

Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60(5): 1018-29.

Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In-vitro activity of tigecycline against multipledrug resistant, including pan-resistant, gram-negative and gram- positive clinical isolates from Greek Hospitals. Antimicrob Agents Chemother 2006; 50(9): 3166–69.

Abdul Sattar, Shahid Ahmad Abbasi, Farah Faqir, Irfan Ali Mirza, Javaid Usman, Ali Faraz. Antimicrobial activity of tigecycline against methicillin resistant Staphylococcus aureus in a tertiary care setting. Pakistan Armed Forces Medical J 2011;1. Available from: http:// 32&t=o

Shareek PS, D Sureshkumar, Ramgopalakrishnan, V Ramasubramanian, KA Ghafur, MA Thirunarayanan. Antibiotic Sensitivity Pattern of Blood Isolates of Acinetobacter Species in a Tertiary Care Hospital: A Retrospective Analysis. American Journal of Infectious Disease 2012;8(1):65-69.

R Insa, E Cercenado, MJ Goyanes, A Morente, E Bouza. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007;59(3): 583-585.

Rouchelle Tellis, Sunil Rao, Amar Lobo. An in-vitro study of tigecycline susceptibility among multidrug resistant bacteria in a tertiary care hospital.International J of Biomedical Research 2012;3(4):192-195.

Pankey GA, Ashcraft DS. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay. Diagn Microbiol Infect Dis 264(3):3004.


  • There are currently no refbacks.